ClinicalTrials.gg
Not yet recruitingNCT07918885Updated Nov 5, 2026

High-Flow Nasal Oxygen-Assisted Deep Extubation Versus Awake Extubation in Morbidly Obese Patients

An interventional study of HFNO-Assisted Deep Extubation and Conventional Awake Extubation in Deep Tracheal Extubation, sponsored by Fayoum University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Fayoum University · Not applicable, Interventional, and Supportive care

Updated Nov 5, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This prospective, randomized controlled trial aims to compare two methods of tracheal extubation after general anesthesia in adults with morbid obesity undergoing elective laparoscopic surgery.

A total of 120 patients will be randomly assigned to one of two groups. In the first group, the breathing tube will be removed while the patient remains deeply anesthetized, followed immediately by heated and humidified high-flow nasal oxygen (HFNO). Patients will then be allowed to awaken without unnecessary stimulation. In the second group, the breathing tube will be removed after the patient is fully awake, followed by conventional oxygen therapy through a face mask.

The primary objective is to determine whether HFNO-assisted deep extubation reduces the incidence of coughing during the first 15 minutes after extubation compared with conventional awake extubation.

The study will also assess respiratory complications, the need for airway interventions, hemodynamic changes, recovery times, and adverse events associated with the two extubation approaches.

The findings may help inform airway management strategies during recovery from general anesthesia in patients with morbid obesity.

02

Conditions studied

  • Deep Tracheal Extubation

Keywords

  • High-Flow Nasal Oxygen
  • Deep Tracheal Extubation
  • No-Touch Extubation
  • Awake Tracheal Extubation
  • Emergence Cough
  • Laparoscopic Surgery
03

In context

Lead sponsor

Fayoum University is the lead sponsor of 148 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18-60 years. • ≥ 40 kg/m² (morbidly obese). • (ASA) physical status classification II-III.

Patients scheduled for elective laparoscopic surgery .

  • Mallampati score I or II (anticipated non-difficult airway).

Exclusion criteria

Exclusion Criteria:

  • Patients with known or anticipated difficult airway (Mallampati III-IV, previous history of difficult intubation, limited mouth opening, or cervical spine immobility).

Patients with severe obstructive sleep apnea (OSA) on home CPAP/BiPAP therapy who cannot tolerate nasal cannula delivery systems.

  • Active gastroesophageal reflux disease (GERD) with aspiration risk.
  • Patients with significant cardiovascular disease ( class III-IV heart failure, unstable angina, or recent myocardial infarction within 6 months).
  • Patients with severe pulmonary disease ( \< 50% predicted, chronic hypercapnia, or oxygen-dependent respiratory failure).
  • Emergency surgical procedures.
  • Patients with nasal obstruction, facial deformity, or conditions precluding HFNO delivery.
  • Pregnant patients.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Group D (Deep Extubation + HFNO Group)

    Patients allocated to this group will undergo tracheal extubation while deeply anesthetized, after confirmation of adequate spontaneous ventilation and neuromuscular recovery (train-of-four ratio ≥0.9). Immediately after extubation, heated and humidified high-flow nasal oxygen (HFNO) will be administered at an initial flow rate of 40 L/min, adjustable up to 60 L/min as clinically indicated. Oxygen concentration will be titrated to maintain SpO₂ ≥92%. HFNO will be continued for 60 minutes in the post-anesthesia care unit (PACU).

    Procedure: HFNO-Assisted Deep Extubation

  • Active comparator
    Group A (Awake Extubation Group)

    Patients allocated to this group will undergo conventional awake tracheal extubation after discontinuation of general anesthesia, once they regain consciousness, respond to verbal commands, and meet standard extubation criteria, including adequate spontaneous ventilation and neuromuscular recovery (train-of-four ratio ≥0.9). Following extubation, supplemental oxygen will be administered through a simple face mask at 8-10 L/min for 60 minutes in the post-anesthesia care unit (PACU).

    Procedure: Conventional Awake Extubation

Interventions

  • ProcedureHFNO-Assisted Deep Extubation

    At the end of surgery, following adequate recovery from neuromuscular blockade (train-of-four ratio ≥0.9) and confirmation of adequate spontaneous ventilation, the endotracheal tube will be removed while the patient remains deeply anesthetized (end-tidal sevoflurane concentration ≥1.0 age-adjusted MAC). Immediately after extubation, heated and humidified high-flow nasal oxygen (HFNO) will be administered through nasal cannulae at an initial flow rate of 40 L/min, which may be increased to 60 L/min as clinically indicated. The initial FiO₂ will be 1.0 and subsequently titrated to maintain SpO₂ ≥92%. HFNO will continue for 60 minutes in the post-anesthesia care unit. Unnecessary stimulation during emergence will be avoided.

  • ProcedureConventional Awake Extubation

    At the end of surgery, general anesthesia will be discontinued, and tracheal extubation will be performed after the patient regains consciousness, responds to verbal commands, and fulfills standard extubation criteria, including adequate spontaneous ventilation and neuromuscular recovery (train-of-four ratio ≥0.9). Following extubation, supplemental oxygen will be administered via a simple face mask at 8-10 L/min for 60 minutes in the post-anesthesia care unit.

06

What researchers measure

Primary outcomes

  1. Incidence of Coughing During Extubation and Early Emergence

    The proportion of patients experiencing at least one episode of coughing during tracheal extubation or within the first 15 minutes after extubation. Coughing will be recorded as a binary outcome (yes/no) for each participant, and the incidence will be compared between the two study groups.

    Time frame: During tracheal extubation and up to 15 minutes post-extubation

Secondary outcomes

  1. Severity of Coughing During Extubation and Early Emergence

    Cough severity will be assessed using the Modified Minogue Cough Scale, a four-grade ordinal scale: Grade 1, no coughing; Grade 2, mild coughing; Grade 3, moderate coughing; and Grade 4, severe coughing. Cough severity will be assessed during tracheal extubation and throughout the first 15 minutes after extubation.

    Time frame: During tracheal extubation and up to 15 minutes post-extubation

  2. Incidence of Laryngospasm

    The proportion of participants who experience laryngospasm during emergence from general anesthesia or within the first 60 minutes after tracheal extubation. Laryngospasm will be recorded as present or absent (yes/no), and any episode will be classified as partial or complete.

    Time frame: During emergence and up to 60 minutes after tracheal extubation

  3. Incidence of Breath-Holding or Apnea

    The proportion of participants experiencing at least one episode of breath-holding or apnea during emergence from general anesthesia or within the first 60 minutes after tracheal extubation. Events will be recorded as present or absent (yes/no), with the type of respiratory event documented when applicable.

    Time frame: During emergence and up to 60 minutes after tracheal extubation

  4. Heart Rate During Emergence and Early Postoperative Recovery

    Heart rate (HR), measured in beats per minute (bpm), will be recorded at pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation. Heart rate measurements at the predefined time points will be compared between the two study groups.

    Time frame: At pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation.

  5. Mean Arterial Pressure During Emergence and Early Postoperative Recovery

    Mean arterial pressure (MAP), measured in millimeters of mercury (mmHg), will be recorded at pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation. Mean arterial pressure measurements at the predefined time points will be compared between the two study groups.

    Time frame: At pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation.

  6. Time From Extubation to Full Orientation

    From tracheal extubation until achievement of full orientation, assessed for up to 60 minutes after extubation.

    Time frame: From tracheal extubation until full orientation during emergence

  7. Length of Stay in the Post-Anesthesia Care Unit

    From admission to the post-anesthesia care unit (PACU) until PACU discharge, assessed for up to 4 hours after admission.

    Time frame: From PACU admission to PACU discharge

  8. Incidence of Bronchospasm

    The proportion of participants experiencing at least one clinically diagnosed episode of bronchospasm during emergence from general anesthesia or within the first 60 minutes after tracheal extubation. Bronchospasm will be recorded as present or absent (yes/no).

    Time frame: During emergence and up to 60 minutes after tracheal extubation

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • 2. Waheed Z, Amatul-Hadi F, Kooner A, Bhatti J, Afzal M, Ahmed R, et al. General anesthetic care of obese patients undergoing surgery: a review of current anesthetic considerations and recent advances. Cureus. 2023;15(7):e41565. 3. Pelosi P, Gregoretti C. Perioperative management of obese patients. Best Practice & Research: Clinical Anaesthesiology. 2010;24(2):211-225. 4. Rosén J, Frykholm P, Fors D. Effect of high-flow nasal oxygen on postoperative oxygenation in obese patients: a randomized controlled trial. Health Science Reports. 2022;5(3):e616. 5. Singh PA, Thong SY, Sivasankar R. Airway management in patients suffering from morbid obesity. Saudi Journal of Anaesthesia. 2022;16(3):314-321. 6. Adams JP, Murphy PG. Obesity in anaesthesia and intensive care. British Journal of Anaesthesia. 2000;85(1):91-108. 7. Smith HC, Kinsella SM, Sellers WFS. A comparison of deep versus awake tracheal extubation in adults: a randomized controlled trial. Regional Anesthesia & Pain Medicine. 2024. doi:10.1136/rapm-2024-105362. 8. Abdelmalak BB, Maheshwari A, Mascha EJ. Evaluation of "no touch" extubation technique on airway-related complications during emergence from general anesthesia. Egyptian Journal of Anaesthesia. 2012;28(2):135-141. 9. Wang YK, Li X, Wei SY, Lv X. The effect of high-flow nasal cannula oxygen therapy on preventing hypoxemia during deep sedation extubation after laparoscopic surgery: a prospective randomized controlled trial. BMC Anesthesiology. 2026. doi:10.1186/s12871-026-03735-w. 10. Petkar S, Wanjari D, Priya V. A comprehensive review on high-flow nasal cannula oxygen therapy in critical care: evidence-based insights and future directions. Cureus. 2024;16(8):e66264. 11. Ferrando C, Puig J, Serralta F, Jimenez V, Gutierrez A, García M, et al. High-flow nasal cannula oxygenation reduces postoperative hypoxemia in morbidly obese patients: a randomized controlled trial. Minerva Anestesiologica. 2019;85(10):1062-1070.
  • Hardt K, Wappler F. Anesthesia for Morbidly Obese Patients. Dtsch Arztebl Int. 2023 Nov 17;120(46):779-785. doi: 10.3238/arztebl.m2023.0216. PubMed 37874129 ↗

Individual participant data

Plan to share: No — There is currently no plan to share individual participant data with external researchers. Study findings will be disseminated through scientific publications and presentations.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Apr 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2026
First posted
Nov 5, 2026
StartEst.
Nov 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07918885
Lead sponsor
Fayoum University
Responsible party
Mina Mahrous, MD (Lecturer of Anesthesiology, Surgical Intensive Care, and Pain Management, Fayoum University) — Principal investigator
First posted
Nov 5, 2026
Start date
Nov 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Ahmed Maged Nadar, M. B. B. Ch
Contact
Ahmed.magednadar@yahoo.com
01019510974
Mina Mahrous Sobhy, M.D
Contact
mms12@fayoum.edu.eg
01025273637
Mohamed Ahmed Hamed Ismail, MD
principal investigator · Fayoum University
Abeer Shaaban Joda Morsi, MD
study director · Fayoum University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion